
ABOUT PA CONSULTING
The future of clinical trials isn’t just faster—it’s smarter, bolder, and more connected. Let’s get there together.
Using our understanding of what’s now, what’s new and what’s next, we help you define the strategy and solutions that will make an impact.
By focusing on end users and their needs, we design solutions that deliver measurable results—whether building online patient communities or transforming data into actionable insights.
Talk to us about:
- Getting to market faster: Align systems and processes so they’re interoperable, creating a seamless flow that accelerates trials and makes you more flexible and adaptable to change.
- Creating amazing experiences: Focus on the needs of end users, designing solutions that transform their experiences—whether through building online patient communities or boosting communication between sites and investigators.
- Being the sponsor of choice: Create digital solutions that help you win loyalty because of the experiences they create, making you the obvious choice when a site is deciding which studies to prioritise.
- Boosting efficiency: Reskill your teams in response to new technologies, breaking down silos, and driving efficiency. In doing so, we help you get life-changing drugs and treatments to patients more quickly.
- Reimagining research processes: Use cutting-edge technology, including AI, to cut through confusion and help you navigate complex and unpredictable research processes with confidence.
CONTACT INFORMATION
PA Consulting
Tower Point, 6th Floor, 27-43 Wormwood St.
Boston, MA 02210
UNITED STATES
Phone: +1 (617) 528 ext. 8648
Contact: Charlie Paterson
FEATURED ARTICLES
-
Explore how clinical trials are integrating Electronic Health Records (EHRs) into trial workflows to better face the increasing demands for efficiency, cost reduction, and improved participant experiences.
-
The PA Consulting Clinical Trials Pulse Report 2024 presents a compelling picture of public perceptions, challenges, and innovation opportunities in clinical trial design and delivery.
-
On February 7, 2025, the NIH introduced a pivotal policy (NOT-OD-25-068), capping indirect cost recovery at 15% for research grants.
-
Clinical trial enrollment remains a major bottleneck in drug development, but consumer-centric innovations could present a solution to enhance every stage of clinical trial enrollment.